60 research outputs found
Establishing key research questions for the implementation of artificial intelligence in colonoscopy - a modified Delphi method
Background and Aims Artificial intelligence (AI) research in colonoscopy is progressing rapidly but widespread clinical implementation is not yet a reality. We aimed to identify the top implementation research priorities. Methods An established modified Delphi approach for research priority setting was used. Fifteen international experts, including endoscopists and translational computer scientists/engineers from 9 countries participated in an online survey over 9 months. Questions related to AI implementation in colonoscopy were generated as a long-list in the first round, and then scored in two subsequent rounds to identify the top 10 research questions. Results The top 10 ranked questions were categorised into 5 themes. Theme 1: Clinical trial design/end points (4 questions), related to optimum trial designs for polyp detection and characterisation, determining the optimal end-points for evaluation of AI and demonstrating impact on interval cancer rates. Theme 2: Technological Developments (3 questions), including improving detection of more challenging and advanced lesions, reduction of false positive rates and minimising latency. Theme 3: Clinical adoption/Integration (1 question) concerning effective combination of detection and characterisation into one workflow. Theme 4: Data access/annotation (1 question) concerning more efficient or automated data annotation methods to reduce the burden on human experts. Theme 5: Regulatory Approval (1 question) related to making regulatory approval processes more efficient. Conclusions This is the first reported international research priority setting exercise for AI in colonoscopy. The study findings should be used as a framework to guide future research with key stakeholders to accelerate the clinical implementation of AI in endoscopy
Gastric adenocarcinoma in a patient re-infected with H. pylori after regression of MALT lymphoma with successful anti-H. pylori therapy and gastric resection: a case report
BACKGROUND: Helicobacter pylori (H. pylori) has been etiologically linked with primary gastric lymphoma (PGL) and gastric carcinoma (GC). There are a few reports of occurrence of both diseases in the same patient with H. pylori infection. CASE PRESENTATION: We report a patient with PGL in whom the tumor regressed after surgical resection combined with eradication of H. pylori infection. However, he developed GC on follow up; this was temporally associated with recrudescence / re-infection of H. pylori. This is perhaps first report of such occurrence. CONCLUSIONS: Possible cause and effect relationship between H. pylori infection and both PGL and GC is discussed. This case also documents a unique problem in management of PGL in tropical countries where re-infection with H. pylori is supposed to be high
LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity.
BACKGROUND
LGR5 serves as a co-receptor for Wnt/β-catenin signalling and marks normal intestinal stem cells; however, its role in colorectal cancer (CRC) remains controversial. LGR5 cells are known to exist outside the stem cell niche during CRC progression, and the requirement for epidermal growth factor (EGF) signalling within early adenomas remains to be fully elucidated.
METHODS
Epidermal growth factor and gefitinib treatments were performed in EGF-responsive LGR5 early adenoma RG/C2 cells. 2D growth assays were measured using an IncuCyte. LGR5 or MEK1/2 silencing studies were executed using siRNA and LGR5 expression was assessed by qRT-PCR and immunoblotting. Ki67 level and cell cycle status were analysed by flow cytometry.
RESULTS
Epidermal growth factor suppresses expression of LGR5 at both the transcript and protein level in colorectal adenoma and carcinoma cells. Suppression of LGR5 reduces the survival of EGF-treated adenoma cells by increasing detached cell yield but also inducing a proliferative state, as evidenced by elevated Ki67 level and enhanced cell cycle progression. Repression of LGR5 further increases the sensitivity of adenoma cells to EGFR inhibition.
CONCLUSIONS
LGR5 has an important role in the EGF-mediated survival and proliferation of early adenoma cells and could have clinical utility in predicting response of CRC patients to EGFR therapy
Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma
<p>Abstract</p> <p>Background</p> <p>Cyclooxygenase-2 (COX-2, <it>PTGS2</it>) plays an important role in colorectal carcinogenesis. COX-2 overexpression in colorectal cancer is inversely associated with microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP). Evidence suggests that MSI/CIMP+ colorectal cancer may arise through the serrated tumorigenic pathway through various forms of serrated neoplasias. Therefore, we hypothesized that COX-2 may play a less important role in the serrated pathway.</p> <p>Methods</p> <p>By immunohistochemistry, we assessed COX-2 expression in 24 hyperplastic polyps, 7 sessile serrated polyp/adenomas (SSA), 5 mixed polyps with SSA and adenoma, 27 traditional serrated adenomas, 515 non-serrated adenomas (tubular adenoma, tubulovillous adenoma and villous adenoma), 33 adenomas with intramucosal carcinomas, 96 adenocarcinomas with serration (corkscrew gland) and 111 adenocarcinomas without serration.</p> <p>Results</p> <p>Strong (2+) COX-2 overexpression was more common in non-serrated adenomas (28% = 143/515) than in hyperplastic polyps (4.2% = 1/24, p = 0.008) and serrated polyps (7 SSAs and 5 mixed polyps) (0% = 0/12, p = 0.04). Furthermore, any (1+/2+) COX-2 overexpression was more frequent in non-serrated adenomas (60% = 307/515) than in hyperplastic polyps (13% = 3/24, p < 0.0001) and serrated polyps (SSAs and mixed polyps) (25% = 3/12, p = 0.03). Traditional serrated adenomas and non-serrated adenomas showed similar frequencies of COX-2 overexpression. Regardless of serration, COX-2 overexpression was frequent (~85%) in colorectal adenocarcinomas. Tumor location was not significantly correlated with COX-2 overexpression, although there was a trend towards higher frequencies of COX-2 overexpression in distal tumors (than proximal tumors) among hyperplastic polyps, SSAs, mixed polyps, traditional serrated adenomas and adenocarcinomas.</p> <p>Conclusion</p> <p>COX-2 overexpression is infrequent in hyperplastic polyp, SSA and mixed polyp with SSA and adenoma, compared to non-serrated and serrated adenoma. COX-2 overexpression becomes more frequent as tumors progress to higher grade neoplasias. Our observations suggest that COX-2 may play a less significant role in the serrated pathway of tumorigenesis; however, COX-2 may still play a role in later stage of the serrated pathway.</p
Specificity of the Localization of Transforming Growth Factor-α Immunoreactivity in Colon Mucosa
Differential expression of cyclo-oxygenase-2 and nuclear beta-catenin in colorectal cancer tissue
Avaliação imunoistoquímica da proteína ciclooxigenase-2 nas neoplasias colorretais e sua relação com fatores patológicos prognósticos Immunohistochemical evaluation of cyclooxygenase-2 in colorectal neoplasias and relationship with pathological factors in prognosis
OBJETIVOS: Avaliar a prevalência da proteína ciclooxigenase-2 (COX-2) nas neoplasias colorretais e sua relação com os parâmetros patológicos prognósticos para o câncer colorretal. MÉTODO: 65 lesões neoplásicas colorretais foram avaliadas através de imunoistoquímica para a presença de COX-2, também foram analisados fatores patológicos prognósticos e estadiamento das lesões. RESULTADOS: A COX-2 expressou-se positivamente em 27% dos adenomas tubulares, 40% dos adenomas vilosos e 70% nos carcinomas. Diferença estatisticamente significante foi obtida na expressão da COX-2 entre adenomas e carcinomas, porém não houve significância nas demais variáveis estudadas. CONCLUSÃO: A expressão da COX-2 parece variar progressivamente com a progressão da lesão neoplásica, mas não influencia os parâmetros patológicos de mau prognóstico.<br>OBJECTIVES: To evaluate the prevalence of cyclooxygenase-2 (COX-2) in colorectal neoplasia and to establish the relationship with pathological factors in the prognosis of colorectal cancer. METHODS: 65 colorectal neoplastic lesions were investigated by immunohistochemistry for the expression of COX-2, along with the pathological factors in prognosis and staging of lesions. RESULTS: COX-2 was positively expressed in 27% of tubular adenomas, 40% of villous adenomas, and 70% of carcinomas. A statistically significant difference was observed among COX-2 expression in adenomas and carcinomas, but such significance was not seen among the other variables studied. CONCLUSION: COX-2 expression seems to correlate positively with the progression of neoplasias, yet with no influence on the pathological patterns of poor prognosis
The Role of Serum Pepsinogen and Gastrin Test for the Detection of Gastric Cancer in Korea
Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy
Histamine-2 receptor expression in gastric mucosa before and after Helicobacter pylori cure
- …